## **Supplementary Material**

### Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients

Serre-Miranda C<sup>1,2,#</sup>, Nobrega C<sup>1,2,#</sup>, Roque S<sup>1,2,#</sup>, Canto-Gomes J<sup>1,2</sup>, Silva CS<sup>1,2</sup>, Vieira N<sup>1,2</sup>, Barreira-Silva P<sup>1,2</sup>, Alves-Peixoto P<sup>1,2</sup>, Cotter J<sup>1,2,3</sup>, Reis A<sup>3</sup>, Formigo M<sup>3</sup>, Sarmento H<sup>3</sup>, Pires O<sup>4</sup>, Carvalho A<sup>1,2,4</sup>, Petrovykh DY<sup>5</sup>, Diéguez L<sup>5</sup>, Sousa JC<sup>1,2</sup>, Sousa N<sup>1,2,6</sup>, Capela C<sup>1,2,4</sup>, Palha JA<sup>1,2,6</sup>, Cunha PG<sup>1,2,3</sup>, Correia-Neves M<sup>1,2,6</sup>

Assay	Supplier	Product	Catalog no.	Technology	Format	Assay Target	Obs
tive	Abbott Diagnostics	SARS-coV-2 IgG assay	06R86	CLIA	lgG	N protein	Requires an Abbott Architect i2000
ntitat ays	Euroimmun	anti SARS-CoV-2 IgG ELISA kit	EI 2606-9601 G	ELISA	lgG	S1 protoin	Requires a regular absorbance microplate
iqua assi	Euroinninun	anti SARS-CoV-2 IgA ELISA kit	EI 2606-9601 A	ELISA	lgA		reader
Sem	Sniho Diagnostia	MAGLUMI® 2019-nCoV (SARS-CoV-2) IgM kit	130219016M	CLIA	IgM	S optigon and N protoin	Requires a MAGLUMI chemiluminescence
	Shibe Diagnostic	MAGLUMI® 2019-nCoV (SARS-CoV-2) IgG kit	130219015M	CLIA	lgG		immunoassay system
	Cellex	qSARS-Cov-2 IgG/IgM Cassette Rapid Test	WI5513C	LFIA	lgM/lgG	N and S Proteins	-
	Getein Biotech,	One step test for novel coronavirus (2019-nCoV)	CG2057	LFIA	Total In	N and S Proteins	_
	inc	IgM/IgG antibody (colloidal gold)	002007		Total 19	N and O T Totomo	
ş	Innovita	2019-nCoV Ab test (colloidal gold), IgM/IgG whole	n/a	LFIA	laM/laG	N and S Proteins	_
ssay		blood/Serum/Plasma Combo	ind .		igin/igo		
e a:	Liming Bio	StrongStep® SARS-CoV-2 IgM/IgG Test	502090	LFIA	lgM/lgG	Not specified	Extremely faint bands.
tativ	Leccurate	SARS-CoV-2 antibody test	K-20-BC-CoV-2	LFIA	laM/laG	Not specified	_
Quali	Leccurate	(colloidal gold immunochromatography)	11-20-110-000-2		igin/igO	Not specified	-
0	Medomics	Rapid IgM-IgG Combined Antibody Test kit for	n/a	LFIA	laM/laG	Not specified	_
		SARS-CoV-2 (ICA)			.9		
	Render	COVID-19 IgM & IgG Test (immunocromatography)	3.2.01.0.1701	LFIA	lgM/lgG	Not specified	-
	SD Biosensor	Standard Q COVID-19 IgM/IgG Duo Test	Q-NCOV-01D	LFIA	lgM/lgG	N Protein	-

### Supplementary Table S1. Assayed commercial tests to detect immunoglobulins specific for SARS-CoV-2 infection.

CLIA; Chemiluminescence Immunoassay; ELISA: Enzyme Linked Immuno-Sorbent Assay; LFIA: Lateral flow immunoassay; n/a: not available; N: nucleocapsid; S: spike

**Supplementary Table S2.** Summary of tests' results from patients with COVID-19, with data organized by patient ID followed by time since symptoms onset. Only depicted patients for which more than one sample was collected. The last column highlights the samples that were not considered for sensitivity calculation (as they would fall in the same time interval; please see methods section).

				set					lg	βG								lg/	١or	lg	N								Т	ota	l Ig					Π	۷۹۷				
Patient ID	Sample ID	Sex	Age	Days since symptoms ons	Abbott	Euroimmune	Snibe	Cellex	Innovita	Leccurate	Liming	Medomics	Render	SD	Euroimmune	Snibe	Cellex	nnovita	Leccurate	liming	Medomics	Pandar	Kender	SD	Euroimmune	Snibe	Cellex	Snibe	Getein	Innovita	l eccurate	Liming	Medomics	Render	SD		Excluded from sens., PPV & I				
004	027 072 109 271	М	66	27 30 33 40																																	yes yes yes		Pos Neg Not	itive ative test	ed
006	316 341 449	F	33	9 12 25																																					
009	037 160	Μ	84	15 23												_																									
010	042 081 177	F	84	10 12 19																																					
	022 061			17 20																			_													╢	yes				
013	123 263	М	63	23 29																																	yes				
	415 462			47 49																																	yes yes yes				
015	009	F	84	58 17																		Ī										F				Ì	yes				
015	331		04	34																	Ļ															ļ					
016	016 073 105	F	67	25 29 31																																	yes yes				
022	126 347	F	49	9 21																	F															Ī					
023	099 258	М	52	2 9																											Ē						yes				
026	336 007 092	M	74	15 9 14																																	yes				
	317			27																	Ļ												F				200				
032	048 068 093 469	М	79	9 10 38																																	<u>yes</u>				
033	047 062 334	F	78	5 7 21																																	yes				
034	010	М	52	15 19																	Ē										ŀ		Ē			Ï					
035	080 140 353 457	м	61	28 32 44 56																																	yes yes				
037	005 023 060 129 261	м	67	16 18 21 25 30																																	yes yes yes yes				

## Supplementary Table S2 (cont.)

				et					Į	gG								lg/	A or	lg	βM				Γ				1	Tota	l Ig					Т	Р٧	
Patient ID	Sample ID	Sex	Age	Days since symptoms onsi	Abbott	Euroimmune	Snibe	Cellex	nnovita	Leccurate	Liming	Medomics	Render	SD	Euroimmune	Snibe	Cellex	Innovita	Leccurate	imina	Medomice		Render	SD	Euroimmune	Snibe	Cellex	Snibe	Getein	Innovita	arciirata	Leceunaic Iming	Medomics	Render	SD	· · ·	Excluded from sens., PPV & N	
038	002 015 043	Μ	78	15 16 18																		_															yes	Positive Negative Not tested
040	185 320	М	90	9 16																																ļ		
043	040	М	63	9 13						F									F			Ī														Ī		
045	079 147	F	91	7 12																																Ī	yes	
	179 019			14 19																	T								Ī							][ ][		
047	067 339	Μ	74	22 37																																	yes	
049	031 106	Μ	82	10 15																																	yes	
051	306 354	F	60	8 12																																┨		
052	041 075	F	80	18 20						-											-															┦	yes	
056	030 076	F	79	10 13																																╡	yes	
060	297 257	F	53	24 14								Ē										Ì						Ē	Ī	Ī			Ē	Ī		ļĻ		
061	323 104	F	79	19																	Ť															j		
064	312 044	F	75	23 23																																		
065	102 259	F	43	27 9					 				Ī					I I	İ	Ì		Ì							Ĺ		İ		Ē		I I		yes	
070	322 063	F	48	14 4																																		
070	286 025	' F	-10 20	15 7																																		
072	342 038		50	25 7																																		
076	098 262	Г	SZ	11 14																																][ ][		
0/8	291		85	16						<u> </u>									ļ																			
079	335 468	F	88	11 25						F									F		ł	1					F						F					
080	054	F	71	10						-			-										_				-								-		Ves	
_	131			16															<u> </u>			1									1						<i>,</i>	
083	020	М	67	22																		1														╢		
084	012	М	45	24																																┋┠	yes	
142	399 427 505	М	73	/ 14 21																		+														╢		
153	444 511	F	85	9 16						Ē									Ī		T	Ŧ						Ī								Ī		
163	361 424	F	47	23 30								F										Ī					F	Ī	Ī		F					Ī	yes	

F: female; Ig: immunoglobulin; M: male; NPV: negative predictive value; PPV: positive predictive value; sens: sensitivity.

**Supplementary Table S3.** Summary of tests' results from healthy controls and HIV-infected controls (samples collected at pre-COVID-19 pandemic), with data organized by group of controls (HIV or healthy), followed by age and sex.

							g	G								lg/	١or	lgN	1							Tota	al Ig	3				l			
Patientient ID	Sex	Age	Abbott	Euroimmune	Snibe	Cellex	Innovita	Leccurate	Liming	Medomics	Render	SD	Euroimmune	Snibe	Cellex	Innovita	Leccurate	Liming	Medomics	Render	SD	Euroimmune	Snibe	Cellex	Getein	Innovita	Leccurate	Liming	Medomics	Render	SD				
HIV 085	М	33																															Po	ositiv	е
HIV 073	F	46																														L	Ne	<u>egativ</u>	ve
HIV 027	М	49																														ιL	No	<u>ot tes</u>	ted
HIV 044	F	51																														l			
HIV 047	F	51																														l			
HIV 048	М	52																														l			
HIV 096	М	55																														l l			
HIV 034	М	57																														ļ			
HIV 089	М	62																														l			
HIV 075	М	63																														l			
HIV 099	М	66																														l l			
HIV 062	М	68																														l l			
HIV 088	М	72																														l			
Healthy 3	F	59																														İ			
Healthy 13	М	59																														İ			
Healthy 27	F	60																														İ			
Healthy 18	М	60																														İ			
Healthy 9	М	60																														İ			
Healthy 35	F	61																														İ			
Healthy 24	F	64																														ĺ			
Healthy 34	М	64																														İ			
Healthy 49	F	65																														İ			
Healthy 38	М	65																														İ			
Healthy 32	F	69																														İ			
Healthy 16	М	69																														ĺ			
Healthy 19	F	71																														İ			
Healthy 43	F	73																														İ			
Healthy 25	М	73																														İ			
Healthy 4	F	75																														ĺ			
Healthy 44	F	75																														ĺ			
Healthy 51	F	75																														i			
Healthy 39	М	75																														i			
Healthy 45	М	76																														i			
Healthy 60	М	76																														i			
Healthy 7	F	79																														i			
Healthy 57	М	79																														İ			
Healthy 58	М	79																														i			
Healthy 37	F	80																														İ			

F: female; Ig: immunoglobulin; M: male.

-

# **Supplementary Table S4.** Summary of tests' results from patients with COVID-19, organized by time since symptoms onset, followed by age and sex.

				ns									lg	G								lgA	or	lgN	1							Tota	al Ig	g						
atient ID	ample ID	xe	ge	ays since sympton nset	linical presentation	ypertension	iabetes	eoplasia	bott	uroimmune	ibe	ellex	novita	eccurate	ming	edomics	ender	0	Iroimmune	libe	elex	novita	eccurate	ming	edomics	ender		Iroimmune	nibe	ellex	etein	novita	eccurate	ming	edomics	ender				
030	ين 1020	М	Å 86			Ť		Z	At	Ш	Sr	Ŭ	Ц	Ľ	1	Σ	Ŗ	SI	Ш	Ś	Ŭ	<u>_</u>	<u>ت</u>		Σ	Å	SI	Ш	S	Ŭ	Ğ	ц	Ľ	Li	Σ	Ŗ	S	ſ	Pos	itivo
030	039	M	52	2	non-sev.	Y	Y	N						_	_					T																			Neg	ative
012	032	F	72	3	sev.	Υ	Ν	Ν																															Not	tested
070	063	F	48 78	4	non-sev.	Y	N	N											_	-					_	-														
055	327	F	52	6	non-sev.	Y	N	N																																
041	026	М	49	7	non-sev.	Υ	Y	Ν																																
076	038	F	52 71	7	non-sev.	N	N	N												$\vdash$	_	$\vdash$		_		_														
142	399	M	73	7	non-sev.	Y	Ν	N																																
033	062	F	78	7	non-sev.	Y	Ν	Ν																																
072	025	F	80 00	7	non-sev.	Y	Y	N											_											_		_								
040	030	F	-00 91	7	sev.	Y	N	Y	-										-	F										-			_	-	_					
029	343	М	50	8	sev.	Y	Ν	Ν																																
051	306	F	60	8	non-sev.	N	N	N													_				_					_		_								
032	314	F	79 88	8	sev.	Y	Ň	N													-				-					-			_		_					
006	316	F	33	9	non-sev.	Ň	N	N																																
014	269	Μ	42	9	non-sev.	Ν	Ν	Ν																																
065	1259	F	43 49	9	non-sev.	N	N	N								_	_			$\vdash$				_	_	_				_		_					_			
023	258	М	52	9	non-sev.	Y	Υ	Ν																																
043	040	М	63	9	non-sev.	Υ	Ν	Ν																																
026	007	M	74	9	non-sev.	Y	Y	Y												_	_	-			_	-				_		_		_						
153	444	F	85	9	non-sev.	N	Y	N																																
040	185	М	90	9	non-sev.	Y	Ν	Y																																
080	054	F	71	10	sev.	Y	Ν	Y																																
032	093	М	79 70	10	sev.	Y	Y	N													_																			
030	030	Г	79 82	10	non-sev.	Y	N	N																								-		_						
010	042	F	84	10	non-sev.	Ŷ	Y	Ν																																
076	098	F	52	11	non-sev.	N	N	N											_																					
079	335 252	F	88 30	11	non-sev.	Y N	N	N									-	_		-	-		_				-			-				_			_			
006	341	F	33	12	non-sev.	Ν	N	Ν																																
067	282	F	56	12	non-sev.	Ν	Y	Ν						_					_																					
019	354 017	F	60 66	12	non-sev.	N	N	N								_														_										
010	081	F	84	12	non-sev.	Y	Y	N																																
045	147	F	91	12	sev.	Y	N	Y																																
003	184	M	59 63	13	sev.	N	N	Y N	_							_	_		_						-	-								_	_	_				
080	089	F	71	13	sev.	Ŷ	N	Y																																
056	076	F	79	13	non-sev.	Y	Ν	Ν																																
093	104	F	79 85	13	non-sev.	Y	Y	N												┢										_										
065	322	F	43	14	non-sev.	N	N	N																																
060	257	F	53	14	non-sev.	Ν	Ν	Ν																																
031	350	Г М	59 71	14	non-sev.	N	N	N														+								_										
142	427	М	73	14	non-sev.	Ý	Ν	Ν																																
026	092	М	74	14	non-sev.	Y	Y	Y																																
078	262 179	F	85 91	14 17	non-sev.	Y	Y N	N																	-															
070	286	F	48	15	non-sev.	Y	N	N																														1		
017	283	F	50	15	non-sev.	Ν	Ν	Ν																																
023	336	M	52	15	non-sev.	Y	Y	N																																
068	300	F	64	15	non-sev.	N	N	N																																
038	002	М	78	15	non-sev.	Y	N	N																																
049	106	M	82 84	15	non-sev.	Y	N	N									-			-			-	-	-	-										_				
009	192	0	89	15	non-sev.	Y	Y	N																																

## Supplementary Table S4 (cont.)

				S	_							l	ΣG								ΙgΑ	or	gM			Т			-	<b>Fotal</b>	g				
				ptor	atior				┢	П	Т	Т	-	Г				-	Ι					Т	Т	╢─	Γ				T	Т			
				sym	sent	ц			1	c,				1				n	1							n									
⊴	₫			JCe	pre:	nsio	s	ia		unu			fe		cs			unu				fe		cs		unu				te te	3	cs			
ent	nple			s sir et	ica	ertei	oete:	plas	Ħ	imr	φ	vita	cura	ing	omi	der		jmr	Φ	ex	vita	cura	ing	omi	der	imr	Ψ	ех	in	vita		lng	der		
Pati	San	Sex	Age	Day	Clin	Hyp	Diał	Neo	Abbo	Eurc	Shib		Leco	Lim	Med	Ren	SD	Eurc	Snib	Cell	nno	Leco	Lim	Med	SD	Euro	Snib	Cell	Gete	Inno		Med	Ren	SD	
081	121	F	45	16	non-sev.	Ν	Ν	Ν																											Positive
037	005	М	67	16	non-sev.	N	N	N								_	_									_					-				Negative
080	015	г М	71 78	16	sev.	Y	N	Y N																			┢				┢				Not tested
095	194	F	82	16	non-sev.	Ý	Y	N																											
078	291	F	85	16	non-sev.	Y	Y	Ν																											
153	029	F	85 86	16 16	non-sev	N Y	Y	N				_															┢					-			
167	404	F	90	16	non-sev.	N	N	N																											
040	320	Μ	90	16	non-sev.	Y	Ν	Y																											
054	214	F	96 54	16 17	Sev.	Y	N	N			+	-	$\vdash$			_	_							_			┢				+	-			
013	022	M	63	17	non-sev.	Y	N	N																											
143	243	М	71	17	non-sev.	Ν	Ν	Y																											
123	231	M	84 84	17	non-sev.	N	N	N			_		-			_	_										┢					_			
135	408	F	87	17	sev.	Y	Y	N					F														┢				t				
133	273	М	94	17	non-sev.	N	N	Ν																											
083	020	M	67	18	non-sev.	Y	N	N				_	-													_	╞					_			
037	023	M	67 78	18 18	non-sev.	Y	N	N																-			$\vdash$				┢				
052	041	F	80	18	non-sev.	Ý	Y	N																											
098	197	М	85	18	non-sev.	Y	N	Ν																_											
074	013	M	39 52	19	non-sev.	N	Y N	N				_	-			_								_			┢				┝	_			
060	323	F	53	19	non-sev.	Ν	N	N																							t				
075	162	F	55	19	sev.	Y	Y	Ν																											
039	028	M	70	19	non-sev.	N	Y	N																		_	_								
047	177	F	74 84	19	non-sev.	Y	Y	N								_															┢		_		
013	061	M	63	20	non-sev.	Ý	Ň	N																											
052	075	F	80	20	non-sev.	Y	Y	Ν				_																							
062	1/4 018	F	83 89	20	non-sev.	Y	N	N				_															┢					-			
022	347	F	49	21	non-sev.	N	N	N																											
037	060	М	67	21	non-sev.	N	N	Ν																											
142	505 334	M F	/3 78	21	non-sev	Y	N	N				_				_	_					_		_			┢					_			
015	069	F	84	21	non-sev.	Ý	Y	N																											
083	088	М	67	22	non-sev.	Y	Ν	Ν																		Ì									
047	067	М	74	22	non-sev.	Y	N	Ν			_																								
084 163	012 361	M	45 47	23	non-sev.	N	N	N					-											_			┢								
069	058	F	56	23	non-sev.	Y	Ν	Ν																											
013	123	М	63	23	non-sev.	Y	Ν	Ν																											
064	044 312	F	/5 79	23	non-sev.	N	Y N	N																									_		
009	160	М	84	23	sev.	Y	N	N																			$\mathbf{T}$								
084	021	М	45	24	non-sev.	Ν	Ν	Ν																											
025	207	M	52	24	non-sev.	N	N	N			+																┢								
006	449	F	33	24	non-sev.	N	N	N					┢									_					F				t				
063	056	F	61	25	non-sev.	Y	Ν	Ν																											
016	016	F	67	25	non-sev.	N	N	N																											
037	342	F	67 80	 25	non-sev.	Y	Y	N								_	-				_			-							t				
079	468	F	88	25	non-sev.	Ŷ	N	N																											
055	011	F	62	26	non-sev.	Y	N	N																											
004	027 317	M	66 74	27	non-sev	Y	N Y	IN Y																											
064	102	F	75	27	non-sev.	N	Y	N																											
058	024	F	55	28	non-sev.	Y	Y	Ν																											
035 134	080 274	M	61 60	28 29	non-sev.	Y N	Y N	N																											
013	263	М	63	29	non-sev.	Y	N	N																											
016	073	F	67	29	non-sev.	Ν	Ν	Ν			Ţ																								
163	424	F	47	30	non-sev.	Ν	Ν	Ν					1																						

## Supplementary Table S4 (cont.)

																				_																				
					smo	uo			lgG													lgA	or I	gМ						-	Fota	ıl Ig								
Dationt ID	ר מוזכוורות	Sample ID	Sex	Age	Days since sympto onset	Clinical Presentati	Hypertension	Diabetes	Neoplasia	Abbott	Euroimmune	Snibe	Cellex	nnovita	Leccurate	Liming	Medomics	Render	SD	Euroimmune	Snibe	Cellex	nnovita	Leccurate	Liming	Medomics	SD	Euroimmune	Snibe	Cellex	Getein	nnovita	Leccurate	Liming	Medomics	Render	SD			
00	)4 (	072	М	66	30	non-sev.	Y	Ν	Ν																													Pos	itive	
03	37	261	М	67	30	non-sev.	Ν	Ν	Ν																													Neg	ative	
01	6	105	F	67	31	non-sev.	Ν	Ν	Ν																													Not	teste	ed
01	.8	164	F	75	31	sev.	Y	Ν	Ν																															
03	35	140	М	61	32	non-sev.	Y	Y	Ν																															
14	15	367	М	66	32	sev.	Y	Ν	Ν																															
14	11 2	281	М	74	32	sev.	Y	Y	Ν																															
00	)4	109	М	66	33	non-sev.	Y	Ν	Ν																		_													
05	59 (	087	F	72	33	non-sev.	Y	Ν	Ν																		_													
13	37 :	277	М	85	33	sev.	Y	Y	Ν																															
13	36 2	276	М	86	33	non-sev.	Ν	Ν	Ν																	_														
01	.3 :	328	М	63	34	non-sev.	Y	Ν	Ν	_					_		_	_						_	_								_		_					
01	.5	331	F	84	34	non-sev.	Y	Y	N						_									_																
02	24	122	F	36	35	non-sev.	N	N	N															_			_						_							
0.	3/ 3	325	M	6/	35	non-sev.	N	N	N	_								_			_			_	_	_	_						_							
02	+/ +	339		/4	3/	non-sev.	Y	IN N	<u>IN</u>						_		_	_	_	_	_			_	_	_	_						_	_	_					
02	23 1	160	Г	70	3/	non-sev.				_					_	_		_	_					_		_							_		_					
10	02 4	409 265	M	79	20	Sev.	T NI	IV	N	_					_	_	_	-		_					_	_	-				_			_	_					
10	20 .	000		64	40	Sev.		N										_		_					_	_	_					_		-	_					
		271	М	66	40	non sev	V	N	N	_								_						_				_					-							
0:	25	271	M	61	40	non-sev	V	V	N	_					_		_	-														_			_	_				
01		415	M	63	47	non-sev	Y	N	N								_	_									+				_									
01	3	462	М	63	49	non-sev	Y	N	N																															
0	35	457	М	61	56	non-sev	Ý	Y	N																															
01	3	530	М	63	58	non-sev.	Ý	N	N																															

F: female; lg: immunoglobulin; M: male; non-serv.: non-severe; N: no; sev.: severe; Y: yes.

**Supplementary Table S5.** Negative and positive predictive values of assayed commercial tests to detect immunoglobulins specific for SARS-CoV-2 infection.

### NEGATIVE PREDICTIVE VALUE

#### POSITIVE PREDICTIVE VALUE

		Negati	ve tests	NPV	95%	6 CI	•	Positiv	/e tests	PPV	95%	6 CI
Commer	cial kit	Tot. ( <i>n</i> )	True (n)	%	Lower	Upper		Tot. ( <i>n</i> )	True (n)	%	Lower	Upper
Abbott	lgG	66	38	57.6	44.8	69.4		93	92	98.9	93.3	99.9
Euroimmun	lgG	70	38	54.3	42.0	66.1		94	94	100.0	95.1	100.0
Snibe	IgG	62	33	53.2	40.2	65.8		90	88	97.8	91.4	99.6
Cellex	lgG	40	22	55.0	38.7	70.4		55	52	94.5	83.9	98.6
Getein												
Innovita	lgG	64	34	53.1	40.3	65.5		69	68	98.6	91.1	99.9
Leccurate	lgG	46	25	54.3	39.2	68.8		49	49	100.0	90.9	100.0
Liming	lgG	74	38	51.4	39.5	63.0		90	90	100.0	94.9	100.0
Medomics	lgG	45	23	51.1	36.0	66.1		41	40	97.6	85.6	99.9
Render	lgG	58	26	44.8	32.0	58.4		56	56	100.0	92.0	100.0
SD	lgG	48	24	50.0	35.4	64.6		47	46	97.9	87.3	99.9
Abbott												
Euroimmun	IgA	56	37	66.1	52.1	77.8		108	107	99.1	94.2	100.0
Snibe	IgM	78	33	42.3	31.4	54.0		74	72	97.3	89.7	99.5
Cellex	IgM	34	19	55.9	38.1	72.4		61	55	90.2	79.1	95.9
Getein												
Innovita	IgM	68	35	51.5	39.1	63.6		65	65	100.0	93.0	100.0
Leccurate	IgM	47	24	51.1	36.3	65.7		48	47	97.9	87.5	99.9
Liming	IgM	80	38	47.5	36.3	58.9		84	84	100.0	94.6	100.0
Medomics	lgM	48	24	50.0	35.4	64.6		38	38	100.0	88.6	100.0
Render	lgM	67	26	38.8	27.4	51.5		47	47	100.0	90.6	100.0
SD	IgM	41	25	61.0	44.5	75.4		54	54	100.0	91.7	100.0
Abbott												
Euroimmun	(IgG;IgA)	54	37	68.5	54.3	80.1		110	109	99.1	94.3	100.0
Snibe	(IgG;IgM)	54	31	57.4	43.3	70.5		98	94	95.9	89.3	98.7
Cellex	(IgG;IgM)	34	19	55.9	38.1	72.4		61	55	90.2	79.1	95.9
Getein	(Total Ig)	39	24	61.5	44.7	76.2		52	51	98.1	88.4	99.9
Innovita	(IgG;IgM)	61	34	55.7	42.5	68.2		72	71	98.6	91.5	99.9
Leccurate	(IgG;IgM)	43	24	55.8	40.0	70.6		52	51	98.1	88.4	99.9
Liming	(IgG;IgM)	70	38	54.3	42.0	66.1		94	94	100.0	95.1	100.0
Medomics	(IgG;IgM)	40	23	57.5	41.0	72.6		46	45	97.8	87.0	99.9
Render	(IgG;IgM)	56	27	48.2	34.8	61.8		59	59	100.0	92.4	100.0
SD	(IgG;IgM)	40	24	60.0	43.4	74.7		55	54	98.2	89.0	99.9

CI: confidence interval; Ig: immunoglobulin; NPV: negative predictive value; PPV: positive predictive value; Tot.: total.



**Supplementary Figure S1.** Results of the 3 semiquantitative testes were correlated between each other for pre-COVID-19 pandemic controls (top graphs) and for all COVID-19 patients, coloured by range of days since symptoms onset (bottom graphs). Solid lines represent each test's cut-off value. In the case of Euroimmun test, the shadowed grey banner refers to borderline values according to the manufacturer (ratio between 0.8 and 1); samples in this area were considered positive. The scale used (logarithmic) does not allow values equal to zero; in these situations, zero values in the Snibe test were replaced by 0.0005 and a dashed grey line was represented in this value.



**Supplementary Figure S2:** Representation of the results from each semiquantitative test, stratified by range of days since symptoms onset. Results from IgG are represented on the top panels and from IgA and IgM in the bottom panels. Each dot represents a single sample, and the horizontal solid lines the group's median. Solid thin black lines represent each test's cut-off value. In the case of Euroimmun test, the shadowed grey banner refers to borderline values according to the manufacturer (ratio between 0.8 and 1.1). The scale used (logarithmic) does not allow values equal to zero, in these situations zero values in the Snibe tests were replaced by 0.0005 and a dashed grey line was represented in this value. When the obtained value was above the detection level in the Euroimmun IgA test, a random value of 20 was attributed (a dashed grey line was represented in this value). Groups were compared using a Kruskal-Wallis test, followed by Dunn's pos-hoc tests; significant differences were represented as follows: comparison with <10 days: \*: p<0.05,\*\*: p<0.01, \*\*\*: p<0.001, and \*\*\*\*: p<0.0001; comparison with 10-15 days:  $^{\text{B}}$ : p<0.05. No other statistical differences are observed. Abbot IgG:  $X^2_{KW}(4, 134) = 23.44$ , p < 0.0001; Euroimmun IgG:  $X^2_{KW}(4, 159) = 18.79$ , p = 0.0002; Euroimmun IgA:  $X^2_{KW}(4, 149) = 9.26$ , p = 0.0260; Snibe IgG:  $X^2_{KW}(4, 145) = 22.49$ , p < 0.0001; Snibe IgM:  $X^2_{KW}(4, 145) = 18.73$ , p = 0.0003.